Overview of NICE’s Elranatamab Managed Ac...

By João L. Carapinha

October 29, 2024

NICE recently recommended Elranatamab as an option for treating relapsed and refractory multiple myeloma in adults with a man...
HIQA’s Strategic Blueprint for Health Care Excellence: Draft Corporate ...
CTO-PCI Technology for Heart Health in Egypt
NICE Rejects Donanemab for NHS Use Due to Cost Concerns
Impact of Health Insurance on Advanced Prostate Cancer Treatment Costs
Telemedicine Growth in the MENA Region: A Digital Healthcare Revolution
Innovative Pricing and Payment Models for Health Technologies
Strengthening Health Systems via Intra-Africa Regulatory Reliance
Saudi Healthcare Reform: Vision 2030 and Beyond
August 2024 Analysis of Türkiye’s Pharmaceutical Foreign Trade
A Decade of Ethical Healthcare Collaboration
UNAIDS Urges Greater Access for Gilead’s Lenacapavir
Early Prevention of Obesity: Tackling from Conception